Stelios Tzellos | Why Timing Matters More Than Most Pharma Launch Teams Realize

Stelios Tzellos

A good oncology drug launched six months too late can lose more market share than a mediocre drug launched at exactly the right moment.

Pharmaceutical companies spend enormous amounts of time discussing product differentiation, pricing strategy, and physician targeting. They spend far less time talking honestly about timing. Yet in oncology, timing often determines whether a launch becomes a market leader or a permanent follower.

Stelios Tzellos of the UK has spent his career analyzing oncology markets across consulting and industry roles, and one lesson has remained remarkably consistent: the market rarely waits for a company to perfect its launch plan.

The Window Closes Faster Than Companies Expect

Oncology markets evolve quickly. Treatment algorithms shift after major conference presentations. Combination regimens emerge unexpectedly. Biomarker testing expands. Competitors accelerate timelines.

A launch strategy built around assumptions from twelve months earlier may already be outdated before the commercial team finalizes its materials.

At GlobalData, Tzellos worked on competitive intelligence and oncology forecasting projects where launch timing assumptions changed repeatedly as new clinical data entered the market. The companies that adapted fastest typically outperformed the ones with theoretically stronger but slower-moving plans.

Why Internal Delays Become Commercial Problems

Inside pharmaceutical companies, delays rarely feel dramatic while they’re happening. One additional market research cycle. Another round of forecasting revisions. Extra approval steps for promotional materials. Additional alignment meetings across functions.

Individually, each delay appears reasonable. Collectively, they can shift a launch into a completely different competitive environment.

At IQVIA, Stelios Tzellos worked with pharmaceutical clients whose launch assumptions sometimes changed more slowly than the markets themselves. By the time the strategy reached execution, competitor dynamics had already evolved.

The Oncology Timing Problem

This issue is particularly severe in oncology because physician adoption patterns are heavily influenced by momentum.

The first therapy to establish itself as part of the treatment narrative often maintains an advantage even after competitors arrive. Physicians build familiarity. Treatment pathways adapt. Institutional protocols solidify.

That means timing is not simply operational. It becomes psychological and behavioural.

Cross-Functional Alignment Determines Speed

At AstraZeneca, where Tzellos leads cross-functional work across business insights, analytics, and oncology marketing, the organizations that move fastest are usually the ones where analytics, medical, and commercial teams work in parallel rather than sequence.

The traditional pharmaceutical structure slows decision making because each function waits for another to finalize its recommendations. Faster organizations build strategy collaboratively from the beginning.

What Companies Need to Change

The pharmaceutical industry likes to think of launch timing as a project management issue. It is actually a strategic issue.

The companies that succeed are not necessarily the ones with the most resources or the strongest clinical data. They are often the ones that recognize when the market is shifting and move decisively before the opportunity narrows.

Stelios Tzellos has spent years working in environments where forecasting, competitive intelligence, and product strategy intersect. The lesson from those experiences is simple: in oncology, being right too late is often indistinguishable from being wrong.